Skip to main content

Table 2 Individual values for miR-21, miR-210 values, and clinical outcome

From: Circulating miR-21 as a prognostic biomarker in HCC treated by CT-guided high-dose rate brachytherapy

Patient

miR-21

miR-210

TTLP (d)

TTSP (d)

ΔCт mean pre-therapy

ΔCт mean post-therapy

2−ΔΔCт

ΔCт mean pre-therapy

ΔCт mean post-therapy

2−ΔΔCт

Responders

1

6.08

6.61

0.69

5.14

5.62

0.72

581

949

2

6.55

7.63

0.48

5.18

8.66

0.09

None

1205

3

6.96

7.34

0.76

4.72

5.35

0.65

None

443

4

6.00

5.86

1.10

7.42

7.17

1.19

854

1178

5

5.66

6.26

0.66

4.87

5.26

0.76

None

940

6

7.29

8.66

0.39

7.20

5.70

2.83

1004

1004

7

6.38

7.27

0.54

5.02

5.76

0.60

None

749

8

6.45

6.64

0.87

4.65

5.34

0.62

None

1224

9

5.79

5.80

0.99

6.25

6.34

0.94

None

875

10

5.30

5.57

0.83

5.36

5.76

0.76

None

883

11

5.93

6.27

0.79

5.94

4.51

2.70

267

867

12

5.52

7.36

0.28

5.17

7.10

0.26

None

386

Non-responders

13

6.53

5.59

1.92

5.34

5.06

1.21

None

457

14

6.94

6.76

1.13

4.82

4.35

1.39

182

351

15

7.03

6.26

1.70

4.62

5.26

0.64

None

457

16

6.02

7.49

0.36

5.82

7.46

0.32

93

275

17

7.38

5.24

4.38

5.22

9.08

0.07

225

475

18

4.66

5.14

0.72

5.80

5.40

1.32

None

183

19

5.94

5.59

1.27

5.62

5.29

1.26

138

442

20

6.16

7.51

0.39

5.02

4.60

1.33

None

475

21

5.76

5.31

1.36

5.37

10.48

0.03

490

592

22

7.74

6.59

2.22

3.58

7.47

0.07

None

155

23

5.92

4.56

2.57

4.20

4.57

0.77

None

34

24

7.02

5.13

3.70

7.12

4.55

5.96

None

312

  1. TTLP, Time to limited progression; TTSP, Time to systemic progression; 2−ΔΔCт = [(Δт post-therapy) − (ΔCт pre-therapy)]; d: days